In different types of tumors, including HCC, lung cancer, and melanoma, NK cells have shown variable responses to PD-1/PD-L1 inhibitors, influenced by the tumor microenvironment and the extent of PD-1 expression on NK cells. This evidence concerns the gene CD274 and hepatocellular carcinoma.